Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies

Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies

Shirish Gadgeel,1 Alice T Shaw,2 Fabrice Barlesi,3 Lucio Crino,4 James CH Yang,5 Anne-Marie Dingemans,6 Dong-Wan Kim,7 Filippo de Marinis,8 Mathias Schulz,8 Shiyao Liu,9 Ravindra Gupta,9 Vlatka Smoljanovic,10 Sai-Hong Ignatius Ou11 1Department of Internal Medicine, Division of Hematology and Oncolog...

Full description

Saved in:
Bibliographic Details
Main Authors: Gadgeel S, Shaw AT, Barlesi F, Crino L, Yang JCH, Dingemans AM, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Smoljanovic V, Ou SHI
Format: article
Language:EN
Published: Dove Medical Press 2019
Subjects:
alectinib
non-small-cell lung cancer
np28673
np28761
time to response
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Online Access:https://doaj.org/article/be4ff09e7ee3407b8b960a718417af5e
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/be4ff09e7ee3407b8b960a718417af5e

Similar Items